Abuse and dependence potential for the non‐benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data
G Hajak, WE Müller, HU Wittchen, D Pittrow… - Addiction, 2003 - Wiley Online Library
Aims The non‐benzodiazepine hypnotics zolpidem and zopiclone, which are indicated for
short‐term treatment of insomnia, were considered originally by physicians as almost devoid …
short‐term treatment of insomnia, were considered originally by physicians as almost devoid …
Role of endothelin and endothelin receptor antagonists in renal disease
W Neuhofer, D Pittrow - European journal of clinical …, 2006 - Wiley Online Library
Endothelin (ET)‐1 is a potent vasoconstrictor peptide with pro‐inflammatory, mitogenic, and
pro‐fibrotic properties that is closely involved in both normal renal physiology and pathology…
pro‐fibrotic properties that is closely involved in both normal renal physiology and pathology…
Low-grade albuminuria and cardiovascular risk: what is the evidence?
…, U Tebbe, WD Paar, P Bramlage, D Pittrow… - Clinical Research in …, 2007 - Springer
Microalbuminuria (MA), conventionally defined as a urinary albumin excretion (UAE) of 30–300
mg/day, is recognised as a marker of endothelial dysfunction. Furthermore, it represents …
mg/day, is recognised as a marker of endothelial dysfunction. Furthermore, it represents …
High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study
…, JR Allenberg, H Darius, R Haberl, S Lange, D Pittrow… - Atherosclerosis, 2004 - Elsevier
We aimed to obtain reliable data on the epidemiology, co-morbidities and risk factor profile
of peripheral arterial disease (PAD) in general medical practise. In the cross-sectional part of …
of peripheral arterial disease (PAD) in general medical practise. In the cross-sectional part of …
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
…, HA Ghofrani, D Huscher, D Pittrow… - European …, 2017 - Eur Respiratory Soc
… and high risk of death; 2) this risk stratification strategy was valid for baseline and follow-up
assessments; 3) risk prediction proved accurate for subgroups of patients with I/D/H-PAH and …
assessments; 3) risk prediction proved accurate for subgroups of patients with I/D/H-PAH and …
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry
…, H Kaemmerer, JSR Gibbs, D Pittrow - International journal of …, 2013 - Elsevier
Background Originally reported to occur predominantly in younger women, idiopathic pulmonary
arterial hypertension (IPAH) is increasingly diagnosed in elderly patients. We aimed to …
arterial hypertension (IPAH) is increasingly diagnosed in elderly patients. We aimed to …
Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease
C Diehm, JR Allenberg, D Pittrow, M Mahn, G Tepohl… - Circulation, 2009 - Am Heart Assoc
Background— Our aim was to assess the mortality and vascular morbidity risk of elderly
individuals with asymptomatic versus symptomatic peripheral artery disease (PAD) in the …
individuals with asymptomatic versus symptomatic peripheral artery disease (PAD) in the …
The predictive value of different measures of obesity for incident cardiovascular events and mortality
Context: To date, it is unclear which measure of obesity is the most appropriate for risk
stratification. Objective: The aim of the study was to compare the associations of various measures …
stratification. Objective: The aim of the study was to compare the associations of various measures …
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary …
…, J Pepke-Zaba, U Schulz, M Gorenflo, D Pittrow… - Circulation, 2014 - Am Heart Assoc
… Dr Pittrow has received speaker fees or honoraria for consultations from Actelion, Bayer,
Boehringer Encysive, Ingelheim, Encysive, Novartis, and Pfizer. Dr Hoeper has received …
Boehringer Encysive, Ingelheim, Encysive, Novartis, and Pfizer. Dr Hoeper has received …
[HTML][HTML] COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
…, KM Olsson, D Huscher, D Pittrow… - European …, 2022 - Eur Respiratory Soc
… -up with the four-stratum model a) from intermediate-low risk to other risk categories, b) from
intermediate-high risk to other risk categories, c) from high risk to other risk categories and d…
intermediate-high risk to other risk categories, c) from high risk to other risk categories and d…